Re-emergence of multi-drug resistant and HIV-associated tuberculosis justifies the search for new anti-TB agents. Mushrooms (Basidiomycetes) and their secondary metabolites are relatively little explored in this respect. A short review of antitubercular mushrooms and their active metabolites is presented here.
BlumbergHM, MichaelK, LeonardJ, JasmerRM. (2005) Update on the treatment of tuberculosis and latent tuberculosis infection. Journal of American Medical Association, 293, 2776–2784.
2.
(a) NewtonSM, LauC, WrightCW. (2000) A review of antimycobacterial natural products. Phytotherapy Research, 14, 303–322;
3.
El SayedKA, BartyzelP, ShenX, PerryTL, ZjawionyJK, HamannMT. (2000) Marine natural products as antituberculosis agents. Tetrahedron, 56, 949–953;
TripathiRP, TewariN, DwivediN, TiwariVK. (2005) Fighting tuberculosis: An old disease with new challenges. Medicinal Research Reviews, 25, 93–131.
7.
PauliGF, CaseRJ, InuiT, WangY, ChoS, FischerNH, FranzblauSG. (2005) New perspectives on natural products in TB drug research. Life Sciences, 78, 485–494.
8.
De SouzaMVN. (2005) Plants and fungal products with activity against tuberculosis. The Scientific World Journal, 5, 609–628.
9.
De SouzaMV. (2006) Marine natural products against tuberculosis. The Scientific World Journal, 6, 847–861.
10.
EhrenbergL, HedstromH, LofgrenN, TankmanB. (1946) Antibiotic effect of agarics on tubercle bacilliSvensk Kemisk Tidskrift, 58, 269–270.
11.
(a) LofgrenN, TakmanB, HedstromH. (1949) An antibiotic from Agaricus (Clitocybe) nebularis Batsch active against mycobacteria. Svensk Farmaceutisk Tidskrift, 53, 321–323;
12.
LofgrenN, LuningB. (1953) The structure of nebularine. Acta Chemica Scandinavica, 7, 225;
13.
LofgrenN, LuningB, HedstromH. (1954) The isolation of nebularine and the determination of its structure. Acta Chemica Scandinavica, 8, 670–680.
14.
RobbinsWJ, KavanaghF, HerveyA. (1947) Antibiotic substances from Basidiomycetes. I. Pleurotus griseus. Proceedings of the National Academy of Sciences of the USA, 33, 171–176.
15.
RobbinsWJ, KavanaghF, HerveyA. (1947) Antibiotic substances from Basidiomycetes. II. Polyporus biformis. Proceedings of the National Academy of Sciences of the USA, 33, 176–182.
16.
KavanaghF, HerveyA, RobbinsWJ. (1949) Antibiotic substances from Basidiomycetes. V. Poria corticola, Poria tenuis, and an unidentified Basidiomycete. Proceedings of the National Academy of Sciences of the USA, 36, 1–7.
17.
DoeryHM, GardnerJF. BurtonHS, AbrahamEP. (1951) Antibiotics from a basidiomycete, Coprinus quadrifidus. Antibiotics and Chemotherapy (Washington, D. C.)1, 409–417.
18.
PalaciosAllendes Y. (1966) Antibacterial activity of the higher fungi of Chile. Anales de la Facultad de Quimica y Farmacia (Universidad de Chile) (1968), 18, 106–113.
19.
KanokmedhakulS, KanokmedhakulK, PrajuabsukT, SoytongK, KongsaereeP, SuksamrarnA. (2003) A bioactive triterpenoid and vulpinic acid derivatives from the mushroom Scleroderma citrinum. Planta Medica, 69, 568–571.
20.
(a) MarkovaN, KussovskiV, DrandarskaI, NikolaevaS, GeorgievaN, RadochevaT. (2003) Protective activity of Lentinan in experimental tuberculosis. International Immunopharmacology, 3, 1557–1562.
21.
DrandarskaI, KussovskiV, NikolaevaS, MarkovaN. (205) Combined immunomodulating effects of BCG and Lentinan after intranasal application in guinea pigs. International Immunopharmacology, 5, 795–803.
22.
AkihisaT.FranzblauSG, TokudaH, TagataM, UkiyaM, MatsuzawaT, MetoriK, KimuraY, SuzukiT, YasukawaK. (2005) Antitubercular activity and inhibitory effect on Epstein-Barr virus activation of sterols and polyisoprenepolyols from an edible mushroom, Hypsizigus marmoreus. Biological and Pharmaceutical Bulletin, 28, 1117–1119.
WoldemichaelGM, FranzblauSG, ZhangF, WangY, TimmemannBN. (2003) Inhibitory effect of sterols from Ruprechtia triflora and diterpenes from Calceolaria pinnifolia on the growth of Mycobacterium tuberculosis. Planta Medica, 69, 628–631.
RuguttJK, RuguttKJ. (2001) Relationships between molecular properties and antimycobacterial activities of steroids. Natural Product Letters, 16, 107–113.
27.
BarrowEW, WestbrookL, BansalN, SulingWJ, MaddryJA, ParkerWB, BarrowWW. (2003) Antimycobacterial activity of 2-methyladenosine. Journal of Antimicrobial Chemotherapy, 52, 801–808.
28.
LongMC, ParkerWB. (2006) Structure-activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis. Biochemical Pharmacology, 71, 1671–1682.
29.
ParkerWB, BarrowEW, AllanPW, ShaddixSC, LongMC, BarrowWW, BansalN, MaddryJA. (2004) Metabolism of 2-methyladenosine in Mycobacterium tuberculosis. Tuberculosis, 84, 327–336.
